Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

AUPH RSS Feed
Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 5/25/2019 3:22:45 PM - Followers: 156 - Board type: Free - Posts Today: 0

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
 

Pipeline

 

Pipeline

Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.

 

AUPH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#7619  Sticky Note https://seekingalpha.com/article/4222803 Lunacy_John Galt 11/16/18 09:25:53 AM
#8460   Luna, I love your conservative estimates. Those estimates Jesspro 05/25/19 03:22:45 PM
#8459   Jess, I agree. The fact that they Lunacy_John Galt 05/25/19 01:01:54 PM
#8458   BR, we just made history in this board. Jesspro 05/25/19 10:03:39 AM
#8457   I did some digging I think your numbers LivingTheDream 05/25/19 08:32:29 AM
#8456   Jess, I realize you didn’t ask for my biotech_researcher 05/25/19 06:54:52 AM
#8455   Luna, by year’s end, Auph has to make Jesspro 05/24/19 10:03:02 PM
#8454   Assuming the BO includes full rights to VOS... Lunacy_John Galt 05/24/19 04:52:45 PM
#8453   Luna, What BO price would you consider nice and Maciste 05/24/19 04:31:20 PM
#8452   Jess, do you have any idea how far biotech_researcher 05/24/19 03:49:31 PM
#8451   I sure hope we get a nice big Lunacy_John Galt 05/24/19 03:42:51 PM
#8450   Xiidra, which is inferior to VOS efficacy wise Jesspro 05/24/19 03:14:39 PM
#8449   VOS for dry eye has a ton of zzaatt 05/24/19 02:33:54 PM
#8448   True nothing 100% LivingTheDream 05/24/19 12:15:28 PM
#8447   I don’t think the chance of failure is biotech_researcher 05/24/19 11:58:59 AM
#8446   Fan, no clue to where he is now. Jesspro 05/24/19 11:11:37 AM
#8445   Nice rebound by the market, at least this Maciste 05/24/19 10:57:53 AM
#8444   Not sue about that. Their posting styles Maciste 05/24/19 10:27:41 AM
#8443   Take the drug to market LivingTheDream 05/24/19 10:08:09 AM
#8442   I do think if they had fare chance LivingTheDream 05/24/19 10:06:35 AM
#8441   Greenleaf was hired for one and only one biotech_researcher 05/24/19 10:02:45 AM
#8440   You’re funny BR nobody was looking at the LivingTheDream 05/24/19 09:59:53 AM
#8439   I think Trading Cyclist is Bourbon on my biotech_researcher 05/24/19 09:57:56 AM
#8438   I can assure you if the LN trial biotech_researcher 05/24/19 09:55:03 AM
#8437   Jess, Off subject, any idea what happened to TC Maciste 05/24/19 09:42:25 AM
#8436   I get your point BR but it’s not LivingTheDream 05/24/19 09:18:56 AM
#8435   What I’m saying is no analysts have modeled biotech_researcher 05/24/19 09:03:46 AM
#8434   Is that what you took out of cc LivingTheDream 05/24/19 08:04:14 AM
#8433   LN Phase 3 data is the only thing biotech_researcher 05/24/19 07:14:57 AM
#8432   Yeah, yesterday’s conference is just a rehash of Jesspro 05/23/19 04:43:14 PM
#8431   Scifi FYI: moosedogger 05/23/19 03:12:13 PM
#8430   The stunning news is we are holding up biotech_researcher 05/23/19 03:01:01 PM
#8429   Not much activity of late on this board. ScifiSailor 05/23/19 02:57:59 PM
#8428   The move has been retracted...... Back to our biotech_researcher 05/21/19 12:55:51 PM
#8427   Thanks Luna. I understand, but it seems like rumrunner528 05/20/19 10:26:54 AM
#8426   Moose, I find that the old adage of biotech_researcher 05/20/19 06:42:55 AM
#8425   "The move has begun........" But which moosedogger 05/20/19 06:27:17 AM
#8424   https://finance.yahoo.com/news/aurinia-pharmaceuticals-present-rbc-capital-20020 Jesspro 05/17/19 04:43:37 PM
#8423   The Ph3 data will possibly be released by Lunacy_John Galt 05/17/19 04:39:58 PM
#8422   I'm hoping someone is up for an options rumrunner528 05/17/19 04:09:33 PM
#8421   The move has begun........ biotech_researcher 05/17/19 01:56:55 PM
#8420   The pros and cons of institutional ownership: moosedogger 05/17/19 10:54:21 AM
#8419   Fintel has improved it's ownership report for AUPH moosedogger 05/17/19 09:33:50 AM
#8418   Better link to Orbimed holdings (thanks Luna): moosedogger 05/17/19 07:12:35 AM
#8417   Link to all of Orbimed Advisors holdings: moosedogger 05/16/19 11:44:12 AM
#8416   Luna- thanks much. Orbimed back is definitely moosedogger 05/16/19 11:36:59 AM
#8415   Luna, lots of new holders in that list. Jesspro 05/16/19 11:16:07 AM
#8414   Hey Moose, Lunacy_John Galt 05/16/19 11:10:39 AM
#8413   Luna re "Orbimed bought 3.1m auph" moosedogger 05/16/19 11:03:29 AM
#8412   Orbimed bought 3.1m auph Lunacy_John Galt 05/16/19 10:27:33 AM
#8411   May I remind you of the rule of opposites? Hotrodder1 05/15/19 05:21:14 PM
PostSubject